However, the prognostic implications of these mutations are often limited, and there is an ongoing debate about the reliability of EGFR, ALK, ROS1, and KRAS for accurately predicting prognosis in NSCLC patients [8,9]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.